Latest DNA vaccination Stories
BLUE BELL, Pa., May 11, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the quarter ended March 31, 2011. Total revenue for the quarter ended March 31, 2011, was $3.1 million, compared with $1.4 million for the same period in 2010.
BLUE BELL, Pa., May 5, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
BLUE BELL, Pa., May 4, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
BLUE BELL, Pa., April 29, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
BLUE BELL, Pa., April 18, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A.
Overcoming the gene silencing barrier opens doors for gene therapy. Lincoln, NE (PRWEB) April 12, 2011 NTC today announced the award of a Small Business Innovation Research (SBIR) Phase II grant award from the National Institute of General Medical Sciences.
The Company's adjuvant gives 70% prevention of infection in primates Atlanta, GA (Vocus/PRWEB) April 12, 2011 GeoVax Labs, Inc.
ATLANTA, April 11, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), announced today that it is expanding its preventative HIV/AIDS vaccine development effort in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S.
Killer T cells begin to divide en route to virus-infected tissue, allowing them to hit the ground running when they arrive.
SAN DIEGO, April 4, 2011 /PRNewswire/ -- OncoSec Medical Incorporated (OTCBB: ONCS), a developer of innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today that on March 24, 2011 it completed its acquisition of certain assets of Inovio Pharmaceuticals, Inc.
- In medieval musical notation, a sign or neume denoting a shake or trill.